US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

22.54

+0.46002.08%

Post-market: 22.540.00000.00%19:40 EDT

Volume:75.27K

Turnover:1.71M

Market Cap:249.19M

PE:-4.47

High:23.10

Open:22.00

Low:21.84

Close:22.08

Loading ...

Overview Company News Filings

Palvella Therapeutics Added to Russell 3000, 2000 Indices

MT Newswires Live

Scotiabank Remains a Buy on Palvella Therapeutics (PVLA)

Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential

BRIEF-Palvella Therapeutics Completes Enrollment In Phase 3 Selva Trial Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations, Exceeding Enrollment Target By Over 25%

Palvella Therapeutics Completes Enrollment in Phase 3 Selva Trial of Qtorin™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

THOMSON REUTERS

Palvella Therapeutics Inc - Top-Line Data Expected in Q1 2026

THOMSON REUTERS

Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate

MT Newswires Live

Palvella Therapeutics granted sixth U.S. patent covering rapamycin

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other Mtor Inhibitors

THOMSON REUTERS

Palvella Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026

Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant

Palvella Therapeutics Inc - Selva Trial on Track to Report Results in Q1 2026

THOMSON REUTERS

Palvella Therapeutics Inc - up to $2.6 Mln in Non-Dilutive Funding Anticipated Over Grant Period

THOMSON REUTERS

Palvella Therapeutics Inc - Top-Line Data From Selva Expected in Q1 2026

THOMSON REUTERS

Palvella Therapeutics Receives Initial Proceeds From FDA Orphan Products Grant to Support Phase 3 Selva Trial of Qtorin™ Rapamycin for Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline

Palvella Therapeutics Advances in Rare Skin Disease Therapies

Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

THOMSON REUTERS

Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":22.54,"timestamp":1751313600000,"preClose":22.08,"halted":0,"volume":75268,"hourTrading":{"tag":"盘后","latestPrice":22.54,"preClose":22.54,"latestTime":"19:40 EDT","volume":1432,"amount":32275.333,"timestamp":1751326836844},"delay":0,"floatShares":5730612,"shares":11055665,"eps":-5.045167,"marketStatus":"Closed","change":0.46,"latestTime":"06-30 16:00:00 EDT","open":22,"high":23.1,"low":21.84,"amount":1705762.781164,"amplitude":0.057065,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.045167,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751356800000},"marketStatusCode":5,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":22.08,"preHourTrading":{"tag":"盘前","latestPrice":22.55,"preClose":22.08,"latestTime":"08:07 EDT","volume":51,"amount":1150.05,"timestamp":1751285230460},"postHourTrading":{"tag":"盘后","latestPrice":22.54,"preClose":22.54,"latestTime":"19:40 EDT","volume":1432,"amount":32275.333,"timestamp":1751326836844},"volumeRatio":0.252601,"impliedVol":0.1848,"impliedVolPercentile":0.2},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":5730612,"roa":"-18.39%","roe":"-89.30%","lyrEps":-7.832217,"volumeRatio":0.252601,"shares":11055665,"dividePrice":0,"high":23.1,"amplitude":0.057065,"preClose":22.08,"low":21.84,"week52Low":6.2,"pbRate":"4.48","week52High":29.27,"institutionHeld":0,"latestPrice":22.54,"eps":-5.045167,"divideRate":0,"volume":75268,"delay":0,"ttmEps":-5.045167,"open":22,"prevYearClose":12,"prevWeekClose":22.08,"prevMonthClose":24.13,"prevQuarterClose":27.99,"fiveDayClose":22.54,"twentyDayClose":24.13,"sixtyDayClose":26.97},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2547099960","title":"Palvella Therapeutics Added to Russell 3000, 2000 Indices","url":"https://stock-news.laohu8.com/highlight/detail?id=2547099960","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547099960?lang=en_us&edition=fundamental","pubTime":"2025-06-30 20:06","pubTimestamp":1751285212,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) said Monday that it has been added to the broad-market Russell 3000 Index and the Russell 2000 Index, effective after the US market opens Monday.The addition comes as part of the 2025 reconstitution of the  Russell indices, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2546483547","title":"Scotiabank Remains a Buy on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546483547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546483547?lang=en_us&edition=fundamental","pubTime":"2025-06-27 19:16","pubTimestamp":1751022998,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report) today and set a price target of $50.00. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2545750281","title":"Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2545750281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545750281?lang=en_us&edition=fundamental","pubTime":"2025-06-24 19:35","pubTimestamp":1750764947,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report), with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strong-buy-rating-backed-by-promising-phase-3-trial-and-market-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strong-buy-rating-backed-by-promising-phase-3-trial-and-market-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2545061416","title":"BRIEF-Palvella Therapeutics Completes Enrollment In Phase 3 Selva Trial Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations, Exceeding Enrollment Target By Over 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545061416","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545061416?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678825,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Completes Enrollment In Phase 3 Selva Trial Of Qtorin Rapamycin For Microcystic Lymphatic Malformations, Exceeding Enrollment Target By Over 25%June 23 (Reuters) - Palvella","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA6RNFCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2545416903","title":"Palvella Therapeutics Completes Enrollment in Phase 3 Selva Trial of Qtorin™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545416903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545416903?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:30","pubTimestamp":1750678200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA6RNFCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2545041640","title":"Palvella Therapeutics Inc - Top-Line Data Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2545041640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545041640?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:30","pubTimestamp":1750678200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA6RNFCT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2544972446","title":"Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2544972446","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544972446?lang=en_us&edition=fundamental","pubTime":"2025-06-18 20:28","pubTimestamp":1750249708,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics  said the US Patent and Trademark Office granted it a patent for claims related to the company's Qtorin 3.9% rapamycin anhydrous gel candidate.The patent provides broad protection through 2038 for anhydrous topical composition and methods of use for the potential microcystic lymphatic malformations treatment, the company said.The drug has already been granted US and Food Drug Administration breakthrough therapy, orphan drug and fast track designations, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2544838974","title":"Palvella Therapeutics granted sixth U.S. patent covering rapamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2544838974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544838974?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:35","pubTimestamp":1750246516,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,329,748 for claims related t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-sixth-u-s-patent-covering-rapamycin-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-granted-sixth-u-s-patent-covering-rapamycin-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2544971255","title":"Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other Mtor Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2544971255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544971255?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:30","pubTimestamp":1750246244,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nFWN3SL0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2542532054","title":"Palvella Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually","url":"https://stock-news.laohu8.com/highlight/detail?id=2542532054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542532054?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:06","pubTimestamp":1749672396,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. held its 2025 Annual Meeting of Stockholders virtually on June 10, 2025. Elaine J. Heron, Ph.D., and Tadd S. Wessel were elected to the Board of Directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2025 fiscal year was ratified. Additionally, the stockholders approved the compensation of the company's named executive officers in 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2025, and is solely responsible for the info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLsdxHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2542338109","title":"BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2542338109","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542338109?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:00","pubTimestamp":1749470428,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026June 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2542819383","title":"Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2542819383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542819383?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:35","pubTimestamp":1749468937,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) received the initial proceeds from a previously announced grant from the FDA Office of Orphan Products Development. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-receives-initial-proceeds-from-fda-orphan-products-grant-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-receives-initial-proceeds-from-fda-orphan-products-grant-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2542748389","title":"Palvella Therapeutics Inc - Selva Trial on Track to Report Results in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2542748389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542748389?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:30","pubTimestamp":1749468600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2542438972","title":"Palvella Therapeutics Inc - up to $2.6 Mln in Non-Dilutive Funding Anticipated Over Grant Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2542438972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542438972?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:30","pubTimestamp":1749468600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2542389705","title":"Palvella Therapeutics Inc - Top-Line Data From Selva Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2542389705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542389705?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:30","pubTimestamp":1749468600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2542389230","title":"Palvella Therapeutics Receives Initial Proceeds From FDA Orphan Products Grant to Support Phase 3 Selva Trial of Qtorin™ Rapamycin for Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2542389230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542389230?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:30","pubTimestamp":1749468600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2540086412","title":"Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline","url":"https://stock-news.laohu8.com/highlight/detail?id=2540086412","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540086412?lang=en_us&edition=fundamental","pubTime":"2025-06-04 09:08","pubTimestamp":1748999336,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. has filed an initial statement of beneficial ownership. The filing identifies Ashley Hartmann Kline as the beneficial owner, serving in the role of Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6H755C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2539108202","title":"Palvella Therapeutics Advances in Rare Skin Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539108202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539108202?lang=en_us&edition=fundamental","pubTime":"2025-05-31 11:55","pubTimestamp":1748663732,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q1 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2538465753","title":"Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465753","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465753?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA3DDGCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2538784465","title":"Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538784465","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538784465?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347200,"startTime":"0","endTime":"0","summary":"Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN 3.9% rapamycin anhydrous gel  for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved. Under Kline's leadership at Dompé, Oxervate, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability. Earlier in her career, Ms. Kline was a member of the commercial team at Genentech and a consultant for Bain and Company. She also held commercial roles at Santen Pharmaceuticals and Adverum Biotech. Ms. Kline earned her M.B.A. from the Kellogg School of Management at Northwestern University with majors in Finance, Decision Science, and Analytical Consulting and a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PVLA","BK4232","BK4120","03160","TISI","BK4585","BK4099","R","BK4139","BK4555","BK4604","BK4022","TM"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-06-27","current":-9.876005,"percent":0.458015,"low":-17.690417,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"high":46.119317,"avg":9.015962,"sd":22.018798,"marketCap":227967812},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812}],"updateTime":1751338857249}}}